Welcome to the world of immunohistochemistry!
📞 800-8581156 📧 info@naim.com.cn
Menu
  • Home
  • Product
  • Service and Support
    • Immunohistochemistry and Pathology
    • Immunohistochemistry Technology Exchange
    • Recommended List and Introduction of Newly Developed IHC
    • Public laboratory
    • Consultation and Feedback
  • News and Information
    • Hotspot Focus
    • Industry News
    • Maxxin Dynamics
    • Meeting Notice
  • Entering Maixin
    • Corporate Culture
    • Maisin Honors
    • Maixin Company Profile
    • Myriad Pathology Foundation Overview
  • Contact us
Close
分类
  • Consultation and Feedback
  • Hotspot Focus
  • Immunohistochemistry and Pathology
  • Immunohistochemistry Technology Exchange
  • Industry News
  • Maxxin Dynamics
  • Meeting Notice
  • News and Information
  • Public laboratory
  • Recommended List and Introduction of Newly Developed IHC
  • Service and Support
  • Uncategorized
Product Search
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Immunohistochemical Antibody Selection Scheme for Spleen Diseases (Part 5)

Introduction:In the previous issue, we provided an in-depth introduction to the application of immunohistochemical antibodies in the di...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

The Role of MUM1 in Melanoma Diagnosis

Introduction:Multiple myeloma oncogene 1 (MUM1) is primarily used for the classification and differentiation of malignant lymphomas. Ho...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Is Breast Cancer Related to Hormones?

Introduction:In 2020, the number of new breast cancer cases worldwide reached 2.26 million, surpassing lung cancer to become the leadin...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Role of Inhibin α Expression in Adrenal Tumors

Introduction:Inhibin α is positively expressed in granulosa cell tumors, Sertoli-Leydig cell tumors, sex cord-stromal tumors, and hepat...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

32nd Week of “Mai Mai” Pathology Reading Notes | Immunohistochemical Markers for the Diagnosis of Malignant Melanoma

Introduction:Malignant melanoma is a highly malignant tumor, but its morphology is diverse and can resemble various epithelial tumors a...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

New Antibody Release // FoxP3: A Rising Star in Tumor Immunity and Prognostic Markers

Introduction:FoxP3 has garnered widespread attention in the field of T cell research. Increasing studies indicate that FoxP3 is express...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Immunohistochemical Diagnosis of Renal Epithelial Tumors (Part 2)

Introduction:In the previous issue, we outlined the basic categories of renal tumors and the roles of markers such as PAX8, PAX2, CD10,...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

The Role of FOXA1 Expression in Different Tumors

Introduction:Forkhead-box protein A1 (FOXA1), also known as HNF3A, is a member of the FOX family of transcription factors. FOXA1 expres...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

New Use of Antibodies // Can NKX3.1 Be Used for Differential Diagnosis of Mesenchymal Chondrosarcoma?

Introduction:As is well known, NKX3.1 is a highly sensitive and specific marker for prostate cancer. The loss of NKX3.1 is an indicator...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

The Past, Present, and Future of HER-2

Introduction:Spring brings clear lake water and the chirping of spring birds. Along with spring comes the approval of the miraculous dr...
Continue reading
  • «
  • ‹
  • 14
  • 15
  • 16
  • 17
  • 18
  • ›
  • »

Copyright © 1993 - 2017 Fuzhou Maixin Biotechnology Development Co., Ltd. MinICP No. 05015562-1 | (Fujian) - Non-commercial - 2017-0010

  • Home
  • Product
  • Service and Support
    • Immunohistochemistry and Pathology
    • Immunohistochemistry Technology Exchange
    • Recommended List and Introduction of Newly Developed IHC
    • Public laboratory
    • Consultation and Feedback
  • News and Information
    • Hotspot Focus
    • Industry News
    • Maxxin Dynamics
    • Meeting Notice
  • Entering Maixin
    • Corporate Culture
    • Maisin Honors
    • Maixin Company Profile
    • Myriad Pathology Foundation Overview
  • Contact us
Sidebar